Presidential Coordinator of the Ghana Pharmaceutical Hub, Dr Bernice Makafui Brempong
Government is planning to set up two pharmaceutical and biomanufacturing hubs in the Eastern and Central Regions, as part of efforts to attract investment, boost local drug production and make Ghana a manufacturing centre for the West African market.
The hubs will provide industrial infrastructure for local and international pharmaceutical companies. They are expected to create opportunities in contract manufacturing, research and development, and the production of medicines and other health products.
The initiative also aims to reduce Ghana's reliance on imported medicines by helping manufacturers expand production and keep more of the industry's economic value in the country.
Addressing the 2026 National Pharmacy Heads’ Retreat in Accra, as special guest of honor, the Presidential Coordinator of the Ghana Pharmaceutical Hub, Dr Bernice Makafui Brempong, said the planned special economic zones would lay the foundation for a major transformation of the pharmaceutical industry.
"We are in the golden era of the pharmaceutical industry," she said, adding that President John Dramani Mahama is committed to transforming the sector.
According to her, the zones will come with investment in contract manufacturing facilities to enable pharmaceutical companies to produce more medicines locally instead of relying on imports.
Construction to begin in 2027<\b>
The 2027 Budget Statement names the Eastern and Central Regions as the locations for the proposed hubs. A state-owned special purpose vehicle is expected to begin construction in 2027.
The hubs will support the production of medicines and vaccines, strengthen local supply chains, and create opportunities for technology transfer and skills development.
GH¢5bn spent on imports annually
Dr Brempong said the initiative would also help redirect some of the money importers and wholesalers currently spend on medicines from overseas to local production.
She estimated that Ghana spends about GH¢5 billion a year on pharmaceutical products from India and China, and argued that expanding domestic manufacturing would let the country keep a significant share of that spending.
"This will create jobs for our people and foreign exchange for the country," she said.
60–80% local production by 2030<\b>
The initiative's broader ambition is to raise the share of Ghana's essential medicine needs produced locally to between 60% and 80% by 2030, while building the capacity to supply pharmaceutical products to other African markets.
The hubs form part of government's US$1 billion Pharmaceutical and Biomanufacturing Compact under its New Economy programme. The programme seeks to strengthen medicine security, create skilled industrial jobs and make Ghana a pharmaceutical export platform for West Africa.
Free primary healthcare depends on medicine supply
Dr Brempong noted that initiatives such as Free Primary Healthcare, the Ghana Medical Trust Fund, Mahama Cares, Strengthened National health insurance and the 24-Hour Health Services are creating new demand for pharmaceutical services, making it necessary to strengthen the systems and workforce that support them.
The Ghana Pharmaceutical Hub will support these reforms by expanding the supply of quality-assured medicines made in Ghana. Approved as a Presidential National Legacy Flagship Initiative, the Hub advances the Accra Reset’s vision of health sovereignty by linking Ghana’s health reforms with investment in local manufacturing. Protecting the jobs and livelihoods of medicine importers, distributors and their employees is central to that effort.
The central idea of the Hub is to organize the market, secure the demand, finance the capacity, manufacture the medicines and supply Ghana and export to West Africa and the entire continent.
The Chairperson for the occasion Dr Martha Gyansa-Lutterodt stressed the importance of a reliable pharmaceutical supply system to the success of government's healthcare initiatives.
She said free primary healthcare can only deliver on its promise if patients can consistently get the medicines they need, use them safely and complete their treatment without interruption, she said free care should not mean out of stock and achieving this requires a competent pharmaceutical workforce and systems that promote reliable, safe and patient-centred care.
DR/MA
BoG Cuts Policy Rate to 11% as Borrowing Costs Continue to Fall